当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
First PARP Inhibitor Ok'd for Breast Cancer
Cancer Discovery ( IF 28.2 ) Pub Date : 2018-03-01 , DOI: 10.1158/2159-8290.cd-nb2018-008
American Association for Cancer Research

The FDA has approved olaparib, a PARP inhibitor, for use in patients with metastatic breast cancer who also carry a germline BRCA1 or BRCA2 mutation. With the January 12 approval, olaparib becomes the first targeted therapy for patients with breast cancer with mutated BRCA.



中文翻译:

第一种PARP抑制剂有望用于乳腺癌

FDA已批准PARP抑制剂olaparib用于患有转移性乳腺癌的患者,这些患者也携带种系BRCA1BRCA2突变。在1月12日获得批准后,奥拉帕尼成为BRCA突变的乳腺癌患者的首个靶向治疗药物。

更新日期:2018-03-02
down
wechat
bug